Which antigens would most likely need to be ruled out on 2 heterozygous cells?

Skip to content

  • FRCPath Haematology
    • Flow Cytometry
    • Coagulation
    • Morphology
    • Transfusion
  • Students / Junior Doctors
    • Anaemia
    • Coagulation
    • MRCP PACES
    • Transfusion
    • Learning Cases
  • About
  • FRCPath Haematology
    • Flow Cytometry
    • Coagulation
    • Morphology
    • Transfusion
  • Students / Junior Doctors
    • Anaemia
    • Coagulation
    • MRCP PACES
    • Transfusion
    • Learning Cases
  • About

  • FRCPath Haematology
    • Flow Cytometry
    • Coagulation
    • Morphology
    • Transfusion
  • Students / Junior Doctors
    • Anaemia
    • Coagulation
    • MRCP PACES
    • Transfusion
    • Learning Cases
  • About

  • View Larger Image

    Which antigens would most likely need to be ruled out on 2 heterozygous cells?

Antibody Identification Panels (Antigrams)

  • If a patient is known to have formed a red cell alloantibody, each new sample must be tested to exclude the formation of further alloantibodies.
  • The setup of a panel for antibody identification is discussed in the previous topic. Here, we will discuss how to interpret an red cell antibody identification panel.

Standard Antibody Identification Panels

Which antigens would most likely need to be ruled out on 2 heterozygous cells?

A standard antibody identification panel comprises reagent red cells from at least 8 group O donors. The panel should support resolution of as many common antibody mixtures as possible.

Not all Antibodies are Significant

Which antigens would most likely need to be ruled out on 2 heterozygous cells?

Step 1: ignore clinically insignificant antibodies. These are typically antibodies which do not react at 37°C.

Look for the Agglutination Pattern

Which antigens would most likely need to be ruled out on 2 heterozygous cells?

Step 2: note the agglutination pattern (i.e., panel cells which react with the patient’s plasma) and look for common expressed antigens.

These antigens should not be expressed on cells with no reaction with the patient’s plasma.

This gives an idea of the possible antigen target of the culprit antibody.

However, exclusion of other antibodies is required for confirmation.

In the example, the antibody is likely to be anti-E because cells 3 and 6 express it, corresponding to the reactive IAT. Antibodies such as anti-c and anti-k are not likely candidates because c and k are expressed by panel cells with no reaction (e.g. cells 4, 5, 7, 8, 9).

Excluding Other Clinically-Significant Antibodies

Which antigens would most likely need to be ruled out on 2 heterozygous cells?

Step 3: take note of panel cells with no reaction with the patient’s plasma.

Which antigens would most likely need to be ruled out on 2 heterozygous cells?

Step 4: exclude antigens on panel cells which have no reaction with the patient’s plasma.

Since they do not cause agglutination with the antibody in the plasma, they can be safely excluded the target of the culprit antibody.

When excluding antigens, exclude them on cells which are homozygous for the antigen in question. This ensures that weaker antibodies which exhibit dosage effects are not inadvertently ruled out.

Exceptions can be made for anti-K, which is very rarely homozygously expressed.

In the example, anti-D can be excluded because cells 1, 2 and 3 are express the D antigen, yet have no reaction with the patient’s plasma.

Which antigens would most likely need to be ruled out on 2 heterozygous cells?

Step 5: exclude all other antibodies by checking each antigen. A minimum of two (ideally three) cells which are homozygous for the antigen in question should be used to exclude it.

In this example, all clinically-significant antibodies except anti-E have been excluded.

Antibody Specificity

Which antigens would most likely need to be ruled out on 2 heterozygous cells?

Step 6: assign the specificity of the antibody. This should only be done once two cells expressing the antigen react with the patient’s plasma (red box), and two cells which do not express the antigen are non-reactive with the patient’s plasma (green box).

Technically, confirmation should include phenotyping of the patient’s own red cells, to ensure that they are antigen-negative for the alloantibody target (alloantibodies should not form against self-antigens).

In this example, cell 3 has a strong 4+ reaction at the IAT phase, while cell 6 has a weaker 2+ reaction. This is likely due to a dosage effect, since cell 4 is homozygous for E (DcE/DcE), while cell 6 is heterozygous (dcE/dce).

Which antigens would most likely need to be ruled out on 2 heterozygous cells?

Step 7: check that the antibody identification results do not conflict with the results from the antibody screen. This guards against mistakes made by inadvertently carrying out antibody identification on the wrong sample.

2 Comments

  1. Sylvia Ann Ducros 14 July 2022 at 2:59 am - Reply

    Cell 3 has a 4+ reaction, not cell 4.

    • LearnHaem 18 November 2022 at 1:27 pm - Reply

      Thanks for the input, we have reformatted this page to make the information presented clearer.

Page load link
Go to Top

Which of the following antigens would most likely need to be ruled out on 2 heterozygous cells?

There are a few antigens that can be ruled out on 2 heterozygous cells: C, E, K.

What is heterozygous antigens?

Heterozygous means you have two different alleles on each gene from mom and dad. Homozygous means you have the same allele on each gene from mom and dad.

Which antibody reacts stronger with homozygous cells?

As shown in Table 5-2, anti-c reacts more strongly with homozygous (cc) cells than it does with heterozygous (Cc) cells, as does anti-e. Note that if the antibody is weak, it may give a false negative result with heterozygous cells.

Which antigen is sensitive to enzyme treatment?

Enzyme treatment enhances the reactivity of alloantibodies to the Rh and Kidd antigens as well as antibodies to carbohydrate antigens (ABO, H, I, P, and Lewis). Enzyme treatment most commonly destroys reactivity to the MNS and Duffy antigens.